RT Journal Article
SR Electronic
T1 MicroRNA-107 Targets IKBKG and Sensitizes A549 Cells to Parthenolide
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 6309
OP 6316
DO 10.21873/anticanres.12987
VO 38
IS 11
A1 SOKVISETH MOENG
A1 HYUN AH SEO
A1 CHO YEAN HWANG
A1 GABRIEL A. CIPOLLA
A1 DONG JIN LEE
A1 HYO JEONG KUH
A1 JONG KOOK PARK
YR 2018
UL http://ar.iiarjournals.org/content/38/11/6309.abstract
AB Background/Aim: Patients with advanced non-small cell lung cancer (NSCLC) frequently face a dismal prognosis because of lack of curative therapies. We, therefore, conducted a preclinical investigation of the therapeutic efficacy of microRNA-107 (miR-107). Materials and Methods: The effects of miR-107 on cell proliferation and target gene expression were studied. Combinatorial effects of miR-107 and parthenolide were evaluated. Results: Cell proliferation was repressed in A549 NSCLC cells transfected with miR-107. Inhibitor of nuclear factor kappa B kinase subunit gamma was directly targeted by miR-107. Overexpression of miR-107 in A549 cells sensitized them to parthenolide along with a marked reduction of cyclin-dependent kinase 2. Conclusion: Our findings unveil an important biological function of miR-107 in regulating lung cancer cell proliferation and elevating an antiproliferative effect of parthenolide on lung cancer cells, suggesting that miR-107 could be beneficial benefit treatment for advanced NSCLC.